Rich Eugene C, Esposito Dominick, Kimmey Laura D, Valenzano Christal Stone, Yong Pierre L
Mathematica Policy Research, 1100 First Street NE, 12th Floor, Washington, DC 20002, USA.
J Comp Eff Res. 2014 Nov;3(6):657-66. doi: 10.2217/cer.14.60.
The American Recovery and Reinvestment Act (ARRA) of 2009 directed US$1.1 billion to the US Department of Health and Human Services for support of comparative effectiveness research (CER). As part of this investment, US Department of Health and Human Services commissioned a midstream evaluation of the ARRA CER portfolio. One goal of the evaluation was to identify issues to consider for a future evaluation of the long-term impact of this portfolio and other CER investments. In planning the ARRA CER evaluation, we developed and revised a conceptual framework and related policy research questions that may be useful to future efforts to assess the impact of CER or patient-centered outcomes research investments. In addition, we explored methodological challenges related to designing an evaluation to assess investments in CER that may be informative to any future plans to evaluate the long-term impact of ARRA CER as well subsequent investments made from the Patient-Centered Outcomes Research Trust Fund.
2009年的《美国复苏与再投资法案》(ARRA)向美国卫生与公众服务部拨款11亿美元,用于支持比较效果研究(CER)。作为这项投资的一部分,美国卫生与公众服务部委托对ARRA的CER项目组合进行中期评估。该评估的一个目标是确定在未来评估该项目组合及其他CER投资的长期影响时需要考虑的问题。在规划ARRA的CER评估时,我们制定并修订了一个概念框架以及相关的政策研究问题,这些对于未来评估CER或以患者为中心的结果研究投资的影响可能会有所帮助。此外,我们探讨了与设计评估以评估CER投资相关的方法学挑战,这些挑战可能会为未来评估ARRA CER的长期影响以及后续从以患者为中心的结果研究信托基金进行的投资的任何计划提供信息。